WC
FOLD

Wexford Capital’s Amicus Therapeutics FOLD Stock Holding History

Wexford Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-254,797
Closed -$3.08M – 102
2018
Q3 		$3.08M Sell
254,797
-61,103
-19% -$855K 0.2% 59
2018
Q2 		$4.93M Buy
315,900
+157,950
+100% +$2.39M 0.32% 37
2018
Q1 		$2.38M Buy
+157,950
New +$2.4M 0.17% 52
2016
Q2 		– Sell
-129,534
Closed -$1.09M – 121
2016
Q1 		$1.09M Buy
+129,534
New +$917K 0.21% 70

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wexford Capital's FOLD Position: Q4 2018 in Review

Wexford Capital sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 254,797 shares — an estimated $3.08M sold.

Wexford Capital first reported a position in FOLD in Q1 2016 and held it in 4 quarters. The position peaked at $4.93M in Q2 2018. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

  • Wexford Capital reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Wexford Capital sold 254,797 Amicus Therapeutics shares in Q4 2018, an estimated $3.08M.
  • Wexford Capital first reported a position in Amicus Therapeutics in Q1 2016 and held it in 4 quarters.
  • Wexford Capital's Amicus Therapeutics position peaked at $4.93M in Q2 2018.
  • 195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Wexford Capital's 13F filing for Q4 2018, filed 14 Feb 2019.